For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 <u>http://www.daiichisankyo.com</u>

Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2014

Tokyo, Japan (March 3, 2014) – Daiichi Sankyo Company, Limited, today announced the following organizational changes taking place from April 1, 2014.

1. DAIICHI SANKYO CO., LTD.

(1) Corporate Strategy Division

In order to enhance the global Edoxaban business strategy—the core mission of the Group's third period mid-term management plan—the current Corporate Strategy Department and the Global Brand Strategy Department under the Corporate Strategy Division will be integrated into the new Corporate Strategy Department.

(2) Vaccine Business Intelligence Division

In order to swiftly establish vaccines as a core business, the Vaccine Business Intelligence Division will be made independent from Japan Company and placed as a Business Unit reporting directly to the CEO.

2. DAIICHI SANKYO HEALTHCARE CO., LTD.

- (1) Sales Division
 - ① In order to effectively implement sales strategy by area, a sales department and branches consisting of the Chain Store Sales Department and 7 Branches will be reorganized into a new organization structure consisting of 3 Sales Departments with 12 Branches.
 - ② In order to effectively take sales measures planned by the head office in the Sales Division and ensure close cooperation between the head office and all Sales Departments, all groups under the current Sales Administration Department will be placed under the direct management of the head of the Sales Division and the Department will be abolished. The name of the Sales Division will be changed into the Sales Administration Division.